Dr. Stanley Schwartz talks about why he doesn’t think that sulfonylureas should be used any longer, emphasizing that although they were useful when there were no alternatives, there are far safer and better drugs available today. More videos in this series with Dr. Schwartz Stanley Schwartz, MD, FACP, FACE: Introduction, …
Read More »Stanley Schwartz, MD: How Do You Determine Beta Cell Function?
Dr. Stanley Schwartz talks about the best way to determine beta cell function and says that there are actually several indicators that might need to be used. He suggests that there may be several steps that need to be taken including genotyping patients, looking at both classic markers and newer …
Read More »Stanley Schwartz, MD: Prescribing Medications for Prediabetes?
Dr. Stanley Schwartz talks about addressing the epidemic of not only diabetes but the growing numbers of prediabetes patients. He reviews the current policy situation and then talks about how he proceeds in his practice with prediabetes patients. He points out that several studies have shown that adding certain medications …
Read More »Stanley Schwartz, MD: Next Steps for a “Beta-Cell-Centric” Approach
Dr. Stanley Schwartz addresses the question of, “Where do we go from here?” regarding the beta-cell centric approach. He notes that there are two ways to approach the question — grassroots and a top-down approach — and says that both avenues should be pursued. He hopes that his his …
Read More »Long-term Use of Sulfonylureas and the Risk of CVD
Diabetic women who use sulfonylureas for a long time could have a higher risk of developing CHD….
Read More »FDA Approves J&J’s Invokamet Combo (SGLT-2 + Metformin)
The US Food and Drug Administration has approved Invokamet, a fixed-dose therapy combining Invokana (canagliflozin) and metformin…. Invokana, a member of the new class of drugs known as sodium glucose co-transporter 2 (SGLT2) inhibitors, was approved in the USA as a single agent in March 2013. The thumbs-up is based …
Read More »Should Non-diabetics Use Diabetes Drugs?
A study involving over 180,000 people showed that patients treated with metformin can live longer than non-diabetics….
Read More »Afrezza: Treating Diabetes in a Physiologic Manner
R. Keith Campbell, RPh, FAADE, FASHP, FAPhA, CDE, Distinguished Professor Emeritus in Diabetes Care/Pharmacotherapy, Washington State University College of Pharmacy The health care crisis created by the explosion of diabetes worldwide is one of society’s greatest challenges. The IDF projects that the prevalence of diabetes by 2030 will be over 550 …
Read More »Too Much Medication for Elderly Diabetes Patients?
As patients become older, they become more vulnerable to the risk of side effects that are present with diabetic medications….
Read More »ADA: Sulfonylureas Along with TZDs May Increase Risk for Fractures in Diabetes
A large database analysis has found that two oral diabetes drug classes, thiazolidinediones (TZDs) and sulfonylureas, both increase the risk for fractures when compared with metformin….
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.